LncRNA NEAT1 is upregulated in recurrent aphthous stomatitis (RAS) and has predictive values

Abstract

Background LncRNA NEAT1 promotes inflammatory responses, which contribute to recurrent aphthous stomatitis (RAS). This study focused on the involvement of NEAT1 in RAS. Methods RT-qPCR and ELISA were performed to determine the expression of NEAT1 and proinflammatory factors (IL-2, IL-1β, and TNF-α) in plasma from patients with a history of RAS and showing symptom (n = 80, S-RAS group), people with a history of RAS but showing no symptom (n = 80, NS-RAS group), and controls without a history of RAS (n = 80, Control group). Correlation analysis was performed with Pearson’s correlation coefficient. S-RAS group received treatmen,t and plasma levels of NEAT1 and proinflammatory factors were compared before and after treatment. S-RAS group was followed up for 12 months, and the recurrence was recorded. Results Plasma NEAT1, IL-2, IL-1β, and TNF-α levels were the highest in the S-RAS group, followed in turn by NS-RAS and control groups. NEAT1 was positively and significantly correlated with IL-2, IL-1β, and TNF-α across S-RAS and NS-RAS samples, but not control samples. After treatment, plasma levels of NEAT1, IL-2, IL-1β, and TNF-α decreased significantly. Moreover, a higher recurrence rate was observed during the follow-up in patients with high plasma NEAT1 levels. Conclusion NEAT1 is upregulated in RAS and correlated with multiple proinflammatory factors. Moreover, NEAT1 has predictive values for RAS.

Elevated serum fibrinogen levels in Chinese patients with minor recurrent aphthous stomatitis: An observational study

“…Notably, higher fibrinogen levels observed after anti‐inflammatory treatment persisted in patients with RAS compared to controls in our study. Other systemic inflammatory parameters, such as plasma TNF‐α levels, were also higher in patients with RAS 50 . Novak et al discovered elevated plasma TNF‐α during quiet systemic episodes in patients with BD 52 …”

“…Colchicine also significantly reduced white cell count in patients with RAS, 3,47 and the monocyte to HDL‐cholesterol ratio in BD 48 . Moreover, anti‐inflammatory drugs regulated immunoglobulin (IgG1, IgG2 and IgG4) proteome expression in BD 49 and decreased plasma and saliva IL‐6 and TNF‐α 42,50 in patients with RAS. TNF‐α antagonists, for instance infliximab, etanercept and adalimumab, have been shown to be effective in the treatment of RAS ulcers and recurrence reduction 51 …”

“…Other systemic inflammatory parameters, such as plasma TNFα levels, were also higher in patients with RAS. 50 Novak et al discovered elevated plasma TNFα during quiet systemic episodes in patients with BD. 52…”

Association of long non-coding RNAs NEAT1, and MALAT1 expression and pathogenesis of Behçet's disease among Egyptian patients

“…In line with our findings, Han et al discovered that plasma levels of NEAT1, IL-2, IL-1, and TNF-α were highest in symptomatic recurrent aphthous stomatitis patients before using colchicine in treatment. Patients with recurrent aphthous stomatitis treated with colchicine had significantly lower plasma levels of NEAT1, IL-2, IL-1, and TNF-α ( Han et al, 2021 ). As a result, NEAT1 is linked to the occurrence of BD, and changes in the plasma level of NEAT1 may be used as a prognostic marker to monitor therapeutic outcomes and predict recurrence of BD.…”

Formulation and Evaluation of Prednisolone Sodium Metazoate-Loaded Mucoadhesive Quatsomal Gel for Local Treatment of Recurrent Aphthous Ulcers: Optimization, In Vitro, Ex Vivo, and In Vivo Studies

“…It is distinguished by various, more often-occurring oval-shaped ulcers with a yellowish pseudomembrane on the ulcer floor and an erythematous border [ 2 ]. With a 50% recurrence rate after three months, these ulcers can affect up to 25% of the general population [ 3 ]. The etiopathogenesis of this condition is still unknown; however, it is thought to be multifactorial.…”